Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience
Authors Meyer C, Pieper CC, Ahmadzadehfar H, Lampe NA, Matuschek EME, Maschke TA, Enkirch SJ, Essler M, Spengler U, Schild HH
Received 20 March 2017
Accepted for publication 14 July 2017
Published 26 September 2017 Volume 2017:10 Pages 4773—4785
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Akshita Wason
Peer reviewer comments 3
Editor who approved publication: Dr Ingrid Espinoza
Carsten Meyer,1,* Claus Christian Pieper,1,* Hojjat Ahmadzadehfar,2 Nina Alexandra Lampe,1 Eva Maria E Matuschek,1 Thomas Adrian Maschke,1 Simon Jonas Enkirch,1 Markus Essler,2 Ulrich Spengler,3 Hans Heinz Schild1
1Department of Radiology, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany, 2Department of Nuclear Medicine, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany, 3Department of Internal Medicine I, University of Bonn, Sigmund-Freud-Strasse, Bonn, Germany
*These authors contributed equally to this work
Purpose: To determine the value of radioembolization (RE) for treatment of unresectable hepatocellular carcinoma (HCC).
Patients and methods: Records of patients undergoing RE for unresectable HCC were retrospectively reviewed. Biochemical and clinical toxicities, imaging response (according to modified Response Evaluation Criteria In Solid Tumors), time-to-progression (TTP) and overall survival (OS) were analyzed. Data were stratified according to clinical and procedural parameters. Univariate and multivariate analyses were performed.
Results: One hundred and fifteen patients (89 male, mean age 69.3 years) underwent 158 REs (119 resin-, 39 glass-based) (Barcelona Clinic Liver Cancer [BCLC]-A: 6.1%, B: 33.9%, C: 60.0%). Median clinical follow-up was 5.9 (0.9–83.5) months. No grade 4 or 5 clinical toxicities were noted. Objective response rate was 35.6%; disease control rate was 76.7%. Median TTP of the treated part of the liver was 4 (0.9–45.4) months. 108/115 patients died during follow-up (median OS 8.4 [0.3–82.8] months after first RE [BCLC-A: 52.8 months, BCLC-B: 12.4 months, BCLC-C: 6.1 months]). On multivariate analysis, baseline Eastern Co-operative Oncology Group status <1, ascites prior to RE and best imaging response were predictors of longer OS. In BCLC-C patients, tumor burden, ascites prior to RE, baseline gamma-glutamyl-transferase and Child–Pugh score were predictive of OS.
Conclusions: RE is safe and effective in carefully selected patients suffering from HCC with a low complication rate. Low baseline Eastern Co-operative Oncology Group status and absence of ascites prior to RE are positive prognostic factors.
Keywords: radioembolization, hepatocellular carcinoma, HCC, locoregional therapy, liver
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]
Other article by this author:
The value of intravoxel incoherent motion model-based diffusion-weighted imaging for outcome prediction in resin-based radioembolization of breast cancer liver metastases
Pieper CC, Meyer C, Sprinkart AM, Block W, Ahmadzadehfar H, Schild HH, MÃ¼rtz P, Kukuk GM
Published Date: 5 July 2016